SUPERNUS PHARMACEUTICALS, INC. Quarterly Income Tax Expense (Benefit) in USD from Q4 2011 to Q3 2024

Taxonomy & unit
us-gaap: USD
Description
Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.
Summary
Supernus Pharmaceuticals, Inc. quarterly/annual Income Tax Expense (Benefit) history and growth rate from Q4 2011 to Q3 2024.
  • Supernus Pharmaceuticals, Inc. Income Tax Expense (Benefit) for the quarter ending September 30, 2024 was $6.45M, a 75.1% decline year-over-year.
  • Supernus Pharmaceuticals, Inc. annual Income Tax Expense (Benefit) for 2022 was $32K, a 99.8% decline from 2021.
  • Supernus Pharmaceuticals, Inc. annual Income Tax Expense (Benefit) for 2021 was $19.8M, a 52.6% decline from 2020.
  • Supernus Pharmaceuticals, Inc. annual Income Tax Expense (Benefit) for 2020 was $41.7M, a 21.1% increase from 2019.
Income Tax Expense (Benefit), Trailing 12 Months (USD)
Income Tax Expense (Benefit), Quarterly (USD)
Income Tax Expense (Benefit), YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q3 2024 $6.45M -$19.4M -75.1% Jul 1, 2024 Sep 30, 2024 10-Q 2024-11-04
Q2 2024 $6.39M +$22.7M Apr 1, 2024 Jun 30, 2024 10-Q 2024-08-06
Q1 2024 $119K +$8.05M Jan 1, 2024 Mar 31, 2024 10-Q 2024-05-08
Q3 2023 $11.3M $25.9M +$28.1M Jul 1, 2023 Sep 30, 2023 10-Q 2024-11-04
Q2 2023 -$16.8M -$16.3M -$19.8M -571% Apr 1, 2023 Jun 30, 2023 10-Q 2024-08-06
Q1 2023 $2.99M -$7.93M +$2.96M +27.2% Jan 1, 2023 Mar 31, 2023 10-Q 2024-05-08
Q4 2022 $32K $9.66M +$10.1M Oct 1, 2022 Dec 31, 2022 10-K 2023-03-09
Q3 2022 -$10M -$2.19M -$9.59M -130% Jul 1, 2022 Sep 30, 2022 10-Q 2023-11-08
Q2 2022 -$427K $3.46M -$4.05M -53.9% Apr 1, 2022 Jun 30, 2022 10-Q 2023-08-08
Q1 2022 $3.62M -$10.9M -$16.1M -308% Jan 1, 2022 Mar 31, 2022 10-Q 2023-05-09
Q4 2021 $19.8M -$391K -$9.32M -104% Oct 1, 2021 Dec 31, 2021 10-K 2023-03-09
Q3 2021 $29.1M $7.4M -$5.32M -41.8% Jul 1, 2021 Sep 30, 2021 10-Q 2022-11-09
Q2 2021 $34.4M $7.51M -$5.03M -40.1% Apr 1, 2021 Jun 30, 2021 10-Q 2022-08-08
Q1 2021 $39.4M $5.24M -$2.28M -30.3% Jan 1, 2021 Mar 31, 2021 10-Q 2022-05-12
Q4 2020 $41.7M $8.93M +$1.14M +14.7% Oct 1, 2020 Dec 31, 2020 10-K 2023-03-09
Q3 2020 $40.6M $12.7M +$1.98M +18.5% Jul 1, 2020 Sep 30, 2020 10-Q 2021-11-05
Q2 2020 $38.6M $12.5M +$2.52M +25.2% Apr 1, 2020 Jun 30, 2020 10-Q 2021-08-06
Q1 2020 $36M $7.52M +$1.62M +27.4% Jan 1, 2020 Mar 31, 2020 10-Q 2021-05-07
Q4 2019 $34.4M $7.78M -$5.09M -39.5% Oct 1, 2019 Dec 31, 2019 10-K 2022-04-13
Q3 2019 $39.5M $10.7M +$2.37M +28.3% Jul 1, 2019 Sep 30, 2019 10-Q 2020-11-06
Q2 2019 $37.2M $10M +$6.9M +221% Apr 1, 2019 Jun 30, 2019 10-Q 2020-08-17
Q1 2019 $30.3M $5.9M +$1.07M +22.1% Jan 1, 2019 Mar 31, 2019 10-Q 2020-05-15
Q4 2018 $29.2M $12.9M -$8.53M -39.8% Oct 1, 2018 Dec 31, 2018 10-K 2021-03-08
Q3 2018 $37.7M $8.36M +$1.41M +20.3% Jul 1, 2018 Sep 30, 2018 10-Q 2019-11-08
Q2 2018 $36.3M $3.12M -$5.94M -65.6% Apr 1, 2018 Jun 30, 2018 10-Q 2019-08-09
Q1 2018 $42.2M $4.83M -$1.1M -18.5% Jan 1, 2018 Mar 31, 2018 10-Q 2019-05-10
Q4 2017 $43.3M $21.4M +$20.2M +1636% Oct 1, 2017 Dec 31, 2017 10-K 2020-02-28
Q3 2017 $23.2M $6.95M +$49.6M Jul 1, 2017 Sep 30, 2017 10-Q 2018-11-09
Q2 2017 -$26.5M $9.06M +$8.65M +2136% Apr 1, 2017 Jun 30, 2017 10-Q 2018-08-09
Q1 2017 -$35.1M $5.93M +$5.73M +2863% Jan 1, 2017 Mar 31, 2017 10-Q 2018-05-10
Q4 2016 -$40.9M $1.23M +$1.02M +479% Oct 1, 2016 Dec 31, 2016 10-K 2019-03-01
Q3 2016 -$41.9M -$42.7M -$42.8M -30163% Jul 1, 2016 Sep 30, 2016 10-Q 2017-11-09
Q2 2016 $960K $405K +$180K +80% Apr 1, 2016 Jun 30, 2016 10-Q 2017-08-03
Q1 2016 $780K $200K +$114K +133% Jan 1, 2016 Mar 31, 2016 10-Q 2017-05-09
Q4 2015 $666K $213K Oct 1, 2015 Dec 31, 2015 10-K 2018-03-01
Q3 2015 $142K Jul 1, 2015 Sep 30, 2015 10-Q 2017-01-20
Q2 2015 $225K Apr 1, 2015 Jun 30, 2015 10-Q/A 2017-01-23
Q1 2015 $86K Jan 1, 2015 Mar 31, 2015 10-Q/A 2017-01-20
Q4 2011 -$16.2M Oct 1, 2011 Dec 31, 2011 10-K 2013-03-15
* An asterisk sign (*) next to the value indicates that the value is likely invalid.